NCT05919849 Supporting Parents in Affirming Their Children's Experiences of Stigma
| NCT ID | NCT05919849 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Yale University |
| Condition | Parent-Child Relations |
| Study Type | INTERVENTIONAL |
| Enrollment | 129 participants |
| Start Date | 2023-11-29 |
| Primary Completion | 2026-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 129 participants in total. It began in 2023-11-29 with a primary completion date of 2026-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to develop and test two brief online writing interventions to improve parental acceptance of sexual and gender minority youth (SGMY) in the Southeast United States.
Eligibility Criteria
Inclusion Criteria: 1. Parents are eligible if they meet the following criteria: 1. Be a parent, grandparent, or any other family member who considers themselves a guardian of an SGMY between 15-29 years old, 2. Live in the Southeast United States (Louisiana, Mississippi, Alabama, Georgia, South Carolina, North Carolina, Tennessee, Arkansas, Kentucky, Florida), 3. Identify as heterosexual and cisgender, and 4. Report non-acceptance of their SGMY. 2. SGMY are eligible if they meet the following criteria: 1. Self-identify as SGM, 2. Are 15-29 years old, 3. Live in the Southeast United States, and 4. Have a parent enrolled in the trial Exclusion Criteria: 3. Any individual who meets any of the following criteria will be excluded from participation in this study: 1. Active mania, psychosis, or suicidality, and 2. Unable to provide informed consent.
Contact & Investigator
John E Pachankis, Ph.D.
PRINCIPAL INVESTIGATOR
Yale University
Frequently Asked Questions
Who can join the NCT05919849 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, studying Parent-Child Relations. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05919849 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05919849 currently recruiting?
Yes, NCT05919849 is actively recruiting participants. Contact the research team at danielle.chiaramonte@yale.edu for enrollment information.
Where is the NCT05919849 trial being conducted?
This trial is being conducted at New Haven, United States, College Park, United States, Nashville, United States, Beersheba, Israel.
Who is sponsoring the NCT05919849 clinical trial?
NCT05919849 is sponsored by Yale University. The principal investigator is John E Pachankis, Ph.D. at Yale University. The trial plans to enroll 129 participants.